Wave Life Sciences Ltd. (NASDAQ:WVE) Director Christian O. Henry Sells 10,500 Shares

Wave Life Sciences Ltd. (NASDAQ:WVE) Director Christian O. Henry sold 10,500 shares of the stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $9.77, for a total value of $102,585.00. Following the completion of the transaction, the director now directly owns 16,115 shares of the company’s stock, valued at $157,443.55. This represents a 39.45 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Wave Life Sciences Stock Performance

NASDAQ:WVE opened at $9.59 on Monday. The firm has a market cap of $1.47 billion, a P/E ratio of -8.64 and a beta of -1.04. Wave Life Sciences Ltd. has a fifty-two week low of $4.25 and a fifty-two week high of $16.74. The firm has a 50-day simple moving average of $10.92 and a two-hundred day simple moving average of $11.59.

Wave Life Sciences (NASDAQ:WVE) last announced its quarterly earnings results on Tuesday, March 4th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.34. The company had revenue of $83.75 million during the quarter, compared to the consensus estimate of $25.60 million. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%. On average, equities research analysts predict that Wave Life Sciences Ltd. will post -1.14 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on WVE. StockNews.com upgraded Wave Life Sciences from a “sell” rating to a “hold” rating in a report on Saturday, March 8th. HC Wainwright reiterated a “buy” rating and issued a $22.00 price target on shares of Wave Life Sciences in a research note on Wednesday, March 5th. Finally, Jefferies Financial Group assumed coverage on shares of Wave Life Sciences in a research note on Tuesday, February 25th. They set a “buy” rating and a $26.00 price objective on the stock. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.60.

Institutional Investors Weigh In On Wave Life Sciences

Institutional investors have recently modified their holdings of the business. Victory Capital Management Inc. raised its position in Wave Life Sciences by 16.6% in the 4th quarter. Victory Capital Management Inc. now owns 14,546 shares of the company’s stock worth $180,000 after buying an additional 2,073 shares during the last quarter. Summit Investment Advisors Inc. raised its holdings in shares of Wave Life Sciences by 31.5% during the fourth quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company’s stock valued at $119,000 after purchasing an additional 2,308 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in Wave Life Sciences during the fourth quarter valued at approximately $40,000. Kraematon Investment Advisors Inc. boosted its holdings in Wave Life Sciences by 24.3% in the fourth quarter. Kraematon Investment Advisors Inc. now owns 19,885 shares of the company’s stock worth $246,000 after purchasing an additional 3,885 shares during the last quarter. Finally, Pictet Asset Management Holding SA grew its position in Wave Life Sciences by 36.0% in the 4th quarter. Pictet Asset Management Holding SA now owns 15,579 shares of the company’s stock worth $193,000 after purchasing an additional 4,120 shares during the period. 89.73% of the stock is owned by hedge funds and other institutional investors.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.